Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

Impact · against what's priced in

Vanda Pharmaceuticals has reported positive Phase III results for NEREUS, showing a significant reduction in GLP-1 induced vomiting, particularly in 'extreme' cases (81% reduction). This provides a concrete path toward a supplemental NDA for a high-attrition segment of a $50B+ market, offering a potential new revenue stream beyond its existing indications.

VNDA+0.80

No priced-in read yet